Clinical Trial Update: Study to Evaluate Safety and Daytime Sedation in Subjects With Parkinson's Disease With Neuropsychiatric Symptoms Treated With Pimavanserin or Low-Dose Quetiapine [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating safety and daytime sedation in Parkinson's disease with neuropsychiatric symptoms comparing pimavanserin to low-dose quetiapine was ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Pimavanserin (pimavanserin)
• Quetiapine (quetiapine)

Snippet

Sponsor: ACADIA Pharmaceuticals Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: TERMINATED | Results posted: 2021-10-14